Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

Servier's $2.5 billion acquisition of Day 1 Biopharmaceuticals is a strategic move to immediately gain a commercial oncology asset (Tovarofenib) and a related clinical pipeline. This highlights a common large pharma strategy of acquiring late-stage or already-marketed products to bypass early development risks and accelerate revenue growth.

The old assumption that small biotechs struggle with commercialization ("short the launch") is fading. Acquirers now target companies like Verona and Intracellular that have already built successful sales operations. This de-risks the acquisition by proving the drug's market viability before the deal, signaling a maturation of the biotech sector.

Merck cited Cedara's extensive, pre-Phase 3 research on pricing and cost-effectiveness as a key factor in its $10B acquisition. This demonstrates that early-stage biotechs can significantly increase their M&A value by proactively building a robust commercial case alongside their clinical development.

The adage 'biotech companies are bought, not sold' means an acquisition is typically not the result of a company actively seeking a buyer. As with Portola's sale to Alexion, it is often a fiduciary responsibility to consider an unsolicited offer, even if the internal plan is independent growth.

GSK's CSO reveals their "bolt-on" deal-making focuses on late-stage clinical assets that may have failed trials or have suboptimal profiles. They acquire these assets when they believe a better trial design or repositioning can unlock the molecule's true potential, as exemplified by their acquisition of Momalotinib.

The acquisition of SC Pharma was driven less by the product itself and more by a strategic imperative to shift from a royalty-dependent model to one where MannKind controls the majority of its revenue. This gives them direct influence over their growth trajectory and aligns with shareholder desire for self-determination.